Clinical trial
Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Atomoxetine on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype
NCT00548327 is registered in ClinicalTrials.gov with National Institute of Mental Health (NIMH) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Atomoxetine on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype
- Lead sponsor
- National Institute of Mental Health (NIMH)
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 31, 2007
- Completion date
- November 30, 2011
- Enrollment
- 11 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.